%0 Journal Article
%T 急性冠脉综合征的代谢组学研究进展<br>Progress in Metabolomics of Acute Coronary Syndromes
%A 段明宇
%A 何军
%J Bioprocess
%P 105-115
%@ 2164-5582
%D 2024
%I Hans Publishing
%R 10.12677/bp.2024.142014
%X 急性冠脉综合征作为冠心病的常见临床表型，是以冠状动脉粥样硬化斑块破溃，并继发完全或不完全闭塞性血栓形成为病理基础的一组临床综合征，有发病急、病情重、病死率高等特点，但其发病机制仍尚不明朗。代谢组学作为一种新兴的平台技术，已成为诊断疾病和探索其发病机制的重要工具。为更好地了解急性冠状动脉综合征的发病机制，现就代谢组学在急性冠脉综合征研究中的应用进展做一综述，为其临床防治和相关风险管理提供见解和思路。<br />
Acute coronary syndrome (ACS) is a group of clinical syndromes that frequently occurs with coronary heart disease. It is characterized by the rupture of atherosclerotic plaque in the coronary arteries with subsequent complete or incomplete occlusive thrombosis. The pathogenesis, however, is still unknown. Metabolomics, an emerging platform technology, has become an essential tool for diagnosing diseases and understanding their pathogenesis. In order to better understand the pathogenesis of acute coronary syndrome, this review tracks the development of metabolomics in the study of ACS, providing deeper knowledge and insights for clinical prevention, treatment, and risk management.
%K 急性冠脉综合征，代谢组学，生物标志物<br>Acute Coronary Syndrome
%K Metabolomics
%K Biomarker
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=89148